September is Gynecologic Cancer Awareness Month. The month serves as a time to bring attention to the warning signs, risk factors, and prevention strategies of gynecological cancers. The American Cancer Society asserts that there will be 115,130 new cases of gynecologic cancer, leading to 32,830 deaths in 2022. Additionally, Yale Medicine states gynecological cancers are uncommon relative to other cancers, however all women are at risk. The risk increases with age.
The five types of gynecologic cancer have varying symptoms, treatments, and risk factors. Out of the five, ovarian and uterine cancer can develop from genetic mutations. The Ovarian Cancer Research Alliance (OCRA), claims, “About 20 to 25 percent of women diagnosed with ovarian cancer have a hereditary tendency to develop the disease”. Conversely, uterine cancer is less commonly hereditary, as only about 5 percent of cases are linked to genetic factors.
How careviso can help
careviso is the only healthcare services company that is singularly focused on molecular diagnostic patient access. We are the market leader and perform over 20,000 prior authorizations each month. Our mission is to remove barriers and improve patient access to diagnostic testing. Our dedicated team has robust experience and knowledge and are dedicated to providing the highest quality service.
careviso is a healthcare technology company supporting everyone involved in diagnostic testing. We created a proprietary platform for payors, physicians, and laboratories that improves patient care through streamlined workflows. By automating the impossible we’re solving the most complex problems in the healthcare industry: prior authorizations and financial transparency.